Common treat-to-target approaches are equally effective compared with additional ultrasound exams for treatment guidance in early rheumatoid arthritis (RA) .
In the ARCTIC and the TaSER trials, a trend toward reduced radiographic progression was observed, when ultrasound was added to the assessment, though the ultrasound did not significantly increase benefit vs a treat-to-target strategy. “Patients who seem to have been successfully treated and are free of clinical signs and symptoms of disease may continue to develop permanent structural joint damage. There is a need to find better ways to identify these patients and prevent this development,” Dr Espen Haavardsholm (Diakonhjemmet Hospital, Oslo, Norway), explained the motivation for the presented study.
Data of 230 patients from the ARCTIC study was analysed to evaluate a possible advantage of incorporating ultrasound on the outcome of MRI inflammation or structural damage. Information about MR...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Depression Closely Related to Fatigue in SLE Patients Next Article
Selective IL-23 Blocker Shows Remarkable Efficacy in Patients with Psoriatic Arthritis »
Table of Contents: ACR 2019
Spotlight on Rheumatoid Arthritis
What is Hot in Systemic Lupus Erythematosus
Spondyloarthritis – the Beat Goes On
Osteoarthritis – State-of-the-Art
Reproductive Issues in Rheumatic Disease
Vasculitis – Novel Treatment Modalities
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.